Navigation Links
UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
Date:11/1/2007

nce in peoples' lives. Forest Laboratories' growing product line includes Lexapro(R) (escitalopram oxalate), an SSRI indicated for adults for the initial and maintenance treatment of major depressive disorder and generalized anxiety disorder; Namenda(R) (memantine HCl), an N-methyl D- aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar(R) * (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan medoxomil- hydrochlorothiazide), an angiotensin receptor blocker and diuretic combination product, each indicated for the treatment of hypertension; and Campral(R) * (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation.

* Benicar is a registered trademark of Daiichi Sankyo, Inc., and Campral

is a registered trademark of Merck Sante s.a.s., subsidiary of Merck

KGaA, Darmstadt, Germany.

Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in the Forest Laboratories' SEC reports, including the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2007, and on Form 10-Q for the period ended June 30, 2007.


'/>"/>
SOURCE Forest Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy
2. Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies
3. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
4. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
5. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
8. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
9. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
10. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
11. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015  CytomX, a biotechnology ... cancer, today announced the creation of scientific and ... clinicians in the fields of cancer immunotherapy and ... advisory boards will provide guidance to CytomX on ... precision immunotherapies and Probody drug conjugates. The company ...
(Date:3/2/2015)... 2015   Mast Therapeutics, Inc. (NYSE ... preliminary findings from a randomized, placebo-controlled, nonclinical study ... stable heart failure produced by intracoronary microembolizations.  The ... the effects of repeat intravenous administration of vepoloxamer ... Consistent with results of a ...
(Date:3/2/2015)... , March 2, 2015  Delcath Systems, Inc. (NASDAQ: ... device company focused on oncology with an emphasis on ... that Company management will participate in the upcoming 27 ... 8-11, 2015 at the Ritz Carlton Laguna Niguel in ... Simpson , PhD, MSN, CRNP, Delcath,s interim President and ...
Breaking Medicine Technology:CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 2CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 3Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 2Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 3Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 4Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 5Mast Announces Results From Nonclinical Study Investigating Repeat Treatment With Vepoloxamer In Advanced Heart Failure 6Delcath To Present At The 27th Annual Roth Conference 2Delcath To Present At The 27th Annual Roth Conference 3
... public health professionals today were honored with GlaxoSmithKline ... through a variety of programs, including school health ... care for at-risk families. All nominees were recognized ... Wilmington during the North Carolina Public Health Association,s ...
... Calif., Oct. 27 Accuray Incorporated (Nasdaq: ARAY ... announced that the Korea Cancer Care Hospital (KCCH) in Seoul, ... marking the first hospital in the country – and Asia ... The recently acquired CyberKnife System is located at the ...
Cached Medicine Technology:GlaxoSmithKline Applauds North Carolina's Child Advocates 2GlaxoSmithKline Applauds North Carolina's Child Advocates 3GlaxoSmithKline Applauds North Carolina's Child Advocates 4GlaxoSmithKline Applauds North Carolina's Child Advocates 5GlaxoSmithKline Applauds North Carolina's Child Advocates 6Eighth CyberKnife System in South Korea Installed and Treating Patients 2Eighth CyberKnife System in South Korea Installed and Treating Patients 3Eighth CyberKnife System in South Korea Installed and Treating Patients 4
(Date:3/2/2015)... 2015 GBCHealth, a prominent business ... sector activities and investments in global health issues, ... new members to serve on the organization’s Board ... Chief Strategist and Co-founder of Partners In Health, ... Huma Abbasi, General Manager of Global Health and ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 “ Wants ... of its monthly AppWatch, which features the latest and ... markets. Andrew Tropeano, a mobile technology expert and host ... viewers how this app helps people evaluate priorities. , ... there’s the Wants and Needs app. The app allows ...
(Date:3/2/2015)... March 02, 2015 Gummy smile reduction ... procedures. Gum reshaping can involve one or several procedures to ... lost gum tissue for a more even gum line. Dr. ... line treatment that can permanently lighten discolored or naturally ... approach, which involves a personalized treatment plan to address a ...
(Date:3/2/2015)... Va. (PRWEB) March 02, 2015 The ... nonprofit authority on the use of health IT to ... white paper, “ICD-10 Testing for Small Providers.” The white ... with a starting point for ICD-10 testing by focusing ... payers to ensure compliance with the October 1, 2015 ...
(Date:3/2/2015)... 2015 LegitScript, LLC, operator ... programs, including those for Internet pharmacy certification, ... and classification, has launched a certification program ... new program, called iCareRx , provides ... the identity of the owner/operator of Internet ...
Breaking Medicine News(10 mins):Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 2Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 3Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 4Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 5Health News:An Application to Evaluate Priorities Was Featured on NewsWatch Television on January 30, 2015 2Health News:Gummy Smile Expert, Dr. Alex Farnoosh, is Now Offering Gum Reshaping Procedures 2Health News:WEDI Releases New White Paper on ICD-10 Testing for Small Providers 2Health News:LegitScript Launches Certification Program for Internet Eyeglass Sellers 2
... Women with breast cancer have more aggressive disease ... obese, according to findings published in the March 15 ... American Association for Cancer Research. , The more ... said Massimo Cristofanilli, MD, associate professor of medicine in ...
... (Nasdaq: MNKD ), focused on discovering, developing and,commercializing ... present at the Cowen and Company Healthcare Conference on ... Copley Place Hotel in Boston, MA., Interested parties ... of the,presentation in the Investor Relations section of the ...
... 17 Citi Conference, CHICAGO, March 13 Brookdale ... management will make a presentation,regarding the Company at the ... at 9:00 a.m. ET at the Loew,s Miami Beach ... webcast live and can be accessed through the,Investor Relations ...
... Absorbed harmlessly in the body, it could replace traditional metal ... stent that is quietly absorbed by the body after it ... has worked well in an international trial, researchers report. , ... the report said. In a one-year follow-up, none of the ...
... The Centers for,Medicare & Medicaid Services (CMS) today ... pressure (CPAP) therapy for Medicare patients,with obstructive sleep ... undergo diagnosis for OSA using a home sleep ... departure from current Medicare,coverage for CPAP and diagnosis ...
... March 13 Policy groups,representing millions of older adults, ... add $20.7 million for the,Centers for Disease Control and ... among older Americans., Each year, one in three ... those who fall require medical treatment. The most recent ...
Cached Medicine News:Health News:Breast cancer more aggressive among obese women 2Health News:Brookdale to Present at Lehman Global Healthcare Conference on March 19 2Health News:Melt-Away Stent Works Well in Trial 2Health News:Melt-Away Stent Works Well in Trial 3Health News:30 National Organizations Issue Call to Action for Congress to Fully Fund Falls Prevention Programming in CDC Budget 2Health News:30 National Organizations Issue Call to Action for Congress to Fully Fund Falls Prevention Programming in CDC Budget 3
... This remarkable anti-reflux valve ... plastic housing which prevents the ... closed when in sitting or ... virtually self-cleaning and interference free ...
... valve is enclosed in a ... the valve from being accidentally ... or reclining positions. The valve ... free ensuring uninterrupted flow and ...
... remarkable anti-reflux valve is enclosed ... which prevents the valve from ... in sitting or reclining positions. ... and interference free ensuring uninterrupted ...
... The VerifyNow (Ultegra) System is a ... measures platelet induced aggregation as an ... consists of an instrument, a disposable ... device contains reagents based on microbead ...
Medicine Products: